SAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• SAB Biotherapeutics Inc SABS.OQ reported a quarterly adjusted loss of $1.09​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -79 cents. The mean expectation of five analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from $-1.15 to -38 cents per share.

• Reported revenue was zero​; analysts expected zero.

• SAB Biotherapeutics Inc's reported EPS for the quarter was a loss of $1.09​.

• The company reported a quarterly loss of $10.11 million.

• SAB Biotherapeutics Inc shares had risen by 24.8% this quarter and lost 42.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for SAB Biotherapeutics Inc is $11.50, about 81% above its last closing price of $2.19

This summary was machine generated from LSEG data August 7 at 05:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)